331 related articles for article (PubMed ID: 3918377)
1. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
Santen RJ; Warner B
Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
[TBL] [Abstract][Full Text] [Related]
3. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.
Warner B; Worgul TJ; Drago J; Demers L; Dufau M; Max D; Santen RJ
J Clin Invest; 1983 Jun; 71(6):1842-53. PubMed ID: 6408125
[TBL] [Abstract][Full Text] [Related]
4. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate.
Smith JA; Glode LM; Wettlaufer JN; Stein BS; Glass AG; Max DT; Anbar D; Jagst CL; Murphy GP
Urology; 1985 Feb; 25(2):106-14. PubMed ID: 3918369
[TBL] [Abstract][Full Text] [Related]
5. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of testosterone production with ketoconazole alone and in combination with a gonadotropin releasing hormone analogue in the rat.
English HF; Santner SJ; Levine HB; Santen RJ
Cancer Res; 1986 Jan; 46(1):38-42. PubMed ID: 3079588
[TBL] [Abstract][Full Text] [Related]
7. Management of metastatic prostatic cancer.
Paulson DF
Urology; 1985 Feb; 25(2 Suppl):49-52. PubMed ID: 3918376
[TBL] [Abstract][Full Text] [Related]
8. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
9. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
[TBL] [Abstract][Full Text] [Related]
11. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
[TBL] [Abstract][Full Text] [Related]
12. Reversibility of androgen deprivation therapy in patients with prostate cancer.
Fridmans A; Chertin B; Koulikov D; Lindenberg T; Gelber H; Leiter C; Farkas A; Spitz IM
J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
[TBL] [Abstract][Full Text] [Related]
13. Long term effects of administration of a gonadotropin-releasing hormone superagonist analog in men with prostatic carcinoma.
Santen RJ; Demers LM; Max DT; Smith J; Stein BS; Glode LM
J Clin Endocrinol Metab; 1984 Feb; 58(2):397-400. PubMed ID: 6420439
[TBL] [Abstract][Full Text] [Related]
14. [Testicular endocrine function in patients with prostatic cancer receiving medical castration by long-term administration of LH-RH agonists].
Isurugi K; Kondo Y; Hirasawa K; Oyamatsu T; Honma Y
Nihon Hinyokika Gakkai Zasshi; 1989 Oct; 80(10):1466-73. PubMed ID: 2513445
[TBL] [Abstract][Full Text] [Related]
15. Leuprolide: a review of its effects in animals and man.
Drago JR; Rohner T; Santen R; Manni A; Lipton A; Harvey H; English H
Br J Clin Pract Suppl; 1985 Mar; 37():4-7, 16-9. PubMed ID: 3931664
[No Abstract] [Full Text] [Related]
16. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
[TBL] [Abstract][Full Text] [Related]
17. Follicle-stimulating hormone (FSH) escape during chronic gonadotropin-releasing hormone (GnRH) agonist and testosterone treatment.
Bhasin S; Berman N; Swerdloff RS
J Androl; 1994; 15(5):386-91. PubMed ID: 7860418
[TBL] [Abstract][Full Text] [Related]
18. Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial.
Garnick MB
Urology; 1986 Jan; 27(1 Suppl):21-8. PubMed ID: 3079935
[TBL] [Abstract][Full Text] [Related]
19. Testicular histology following chronic gonadotropin-releasing hormone agonist treatment.
Rajfer J; Swerdloff RS; Heber DM
Fertil Steril; 1984 Nov; 42(5):765-71. PubMed ID: 6436070
[TBL] [Abstract][Full Text] [Related]
20. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
